$0.48
$-0.02 (-4.00%)
End-of-day quote: 05/15/2024
NasdaqCM:BCLI
Brainstorm Cell Therapeutics Annual Report
| Year | Year | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
$0.00M | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M | ||
| GM % | Gross Margin % |
|
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| OM | Operating Margin |
|
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| EPS | Earnings Per Share |
|
$0.00 | $-0.51 | $-0.66 | $-0.68 | $-1.07 | $-1.06 | $-0.70 | $-0.26 | $-0.27 | $-0.46 | $-0.68 |
| Div. | Dividends |
|
$0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||
| PR % | Payout Ratio % |
|
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Sha. | Shares |
|
36.69m | -173.53m | 35.16m | 23.17m | 20.76m | 18.98m | 18.69m | 18.64m | 15.28m | ||
| OCF | Operating Cash Flow |
|
$-19.32M | $-24260000.00M | $-35.19M | $-11.25M | $-12.39M | $-2.36M | $-5.86M | $-7.41M | $-4.49M | ||
| FCF | Free Cash Flow |
|
$-19.35M | $-24590000.00M | $-35.57M | $-11.72M | $-12.76M | $-2.54M | $-5.96M | $-7.45M | $-4.65M | ||
| FCFS | Free Cash Flow Per Share |
|
$-0.53 | $-0.74 | $-1.19 | $-0.54 | $-0.64 | $-0.14 | $-0.32 | $-0.40 | $-0.34 |
